Alkermes plc. reports that David Joseph Gaffin, EVP, CLO of Alkermes, Inc., sold 2,034 ordinary shares on October 2, 2026, at $41.03 per share. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted November 19, 2025. Following the sale, Gaffin directly held 221,388 ordinary shares.
Alkermes plc. officer David Joseph Gaffin reported a proposed sale of 2,034 common shares through Merrill Lynch, with an aggregate market value of $83,455.02 and an approximate sale date of October 2, 2026. Gaffin also reported four prior sales of 2,034 shares each on June 4, July 6, August 3 and September 3, 2026, with gross proceeds of $87,563.70, $109,897.02, $98,811.72 and $97,652.34, respectively.
Alkermes plc (ALKS) reported positive topline results from a phase 1b, proof‑of‑concept study of ALKS 7290, its novel oral orexin 2 receptor agonist, in adults with attention-deficit hyperactivity disorder (ADHD). The study in healthy volunteers and 50 adults with ADHD met its primary objective of characterizing safety, tolerability, pharmacokinetics and pharmacodynamics.
In adults with ADHD, ALKS 7290 was generally well tolerated and produced dose‑dependent, clinically meaningful median reductions at day 14 on exploratory efficacy scales: 14.0 points and 19.0 points on the 54‑point AISRS for the 20 mg and 50 mg doses, and 1.0 and 2.0 point reductions on CGI‑S, indicating shifts from markedly or moderately ill to mildly ill. No serious treatment-emergent adverse events were reported, and most adverse events were mild.
The company stated that these data provide the first clinical evidence of the effects of an orexin receptor agonist in ADHD and support the dose range selected for an ongoing, well‑powered phase 2 study of ALKS 7290 in adults with ADHD, which is enrolling approximately 312 participants with data expected in 2027.
Alkermes plc. (ALKS) filed an initial statement of beneficial ownership reporting that Anne Clem Whitaker is a director of the company. The filing does not list any securities transactions or current holdings and includes an exhibit for a Power of Attorney.
Alkermes plc (ALKS) reported that its board of directors increased in size from ten to eleven members and appointed Anne C. Whitaker as an independent director effective September 14, 2026, with an initial term expiring at the 2027 annual general meeting of shareholders. For her board service, she will receive cash and equity compensation consistent with the company’s standard director program. In connection with her appointment, she is expected to receive in October 2026 a new director equity award with an aggregate target value of $600,000, split 50% stock options and 50% restricted stock unit awards, vesting in three equal annual installments starting on the first anniversary of grant, subject to continuous service. Alkermes also entered into indemnification arrangements with Ms. Whitaker and issued a press release on September 16, 2026, announcing her appointment.
Alkermes plc. (ALKS) reported that executive vice president and chief legal officer David Joseph Gaffin sold 2,034 Ordinary Shares on September 3, 2026 at $48.01 per share in a market transaction. After this sale, he holds 223,422 Ordinary Shares directly, and the transaction was made under a Rule 10b5-1 trading plan adopted on November 19, 2025.
Alkermes plc. (ALKS) has a notice filed under Rule 144 for potential sales of common stock by officer David Joseph Gaffin, with Merrill Lynch identified in connection with the transaction and NASDAQ listed as the market. The notice also lists prior acquisitions of shares through vesting of restricted stock unit awards under the issuer’s equity compensation plan and multiple sales of common stock reported during the past three months, each with stated dates and corresponding share and dollar figures.
Alkermes plc (ALKS) reported insider activity by Craig C. Hopkinson, EVP R&D and Chief Medical Officer. On 2026-09-01, he exercised 5,000 Employee Stock Options at an exercise price of $24.59 per share to acquire 5,000 Ordinary Shares, and sold 9,000 Ordinary Shares at a weighted average price of $46.986 per share. The option exercise and sale were effected pursuant to a Rule 10b5-1 trading plan adopted on 2025-03-14. After the option exercise, he held 61,276 stock options of this grant, which are fully vested in accordance with their terms.
Alkermes plc. (ALKS) received a Rule 144 notice from officer Craig C. Hopkinson covering potential sales of its ordinary shares. The notice lists 9,000 ordinary shares held at Merrill Lynch and an issuer share count of 167,763,272 ordinary shares outstanding as of 09/01/2026.
Shares to be sold include 5,000 shares from an employee stock option exercise on 09/01/2026, 1,898 shares from vesting of a performance share award on 02/05/2026, and 2,102 shares from vesting of restricted stock units on 02/23/2026. The filing also lists several prior sales of 9,000-share blocks between March and August 2026.
Alkermes plc. SVP and Chief Commercial Officer Christian Todd Nichols reported open-market sales of Alkermes ordinary shares. On 2026-08-17, he sold 6,912 shares at a weighted average price of $49.1851 and 664 shares at a weighted average price of $49.6526, in transactions made under a Rule 10b5-1 trading plan. Each sale was executed through multiple trades within disclosed price ranges.